Navigation Links
New drug to tackle fat problems
Date:4/27/2012

Medical researchers at the University of Sheffield have defined the structure of a key part of the human obesity receptor- an essential factor in the regulation of body fat- which could help provide new treatments for the complications of obesity and anorexia.

This major advance in research, published in the journal Structure, will greatly enhance the ability to generate drugs which can both block and stimulate the receptor for the obesity hormone leptin. This could have life-changing effects on people suffering from the complications of obesity and malnutrition.

Researchers have solved the challenging crystal structure of the leptin-binding domain of the obesity receptor using state of the art X-ray crystallography, helping them to work out how to block or stimulate the receptor. Leptin, the obesity hormone, is produced by fat and excess leptin predisposes overweight people to conditions such as multiple sclerosis, cancer and heart disease whilst a deficiency in leptin, as occurs in malnutrition, results in infertility and immunodeficiency.

Blocking the receptor, and therefore the excessive actions of leptin, could prevent the complications of obesity and stimulating the receptor may improve fertility and the immune response.

Professor Richard Ross, Professor of Endocrinology at the University of Sheffield said: "This pioneering research gives us the potential to generate new drugs that could treat conditions and diseases associated with obesity such as Multiple Sclerosis, diabetes and cardiovascular disease.

"Modulating the actions of the obesity receptor provides a novel approach to the treatment of conditions associated with both obesity and anorexia and has the potential to make a massive difference to millions of people whose quality of life and health is hindered by obesity or malnutrition."

Controlling appetite is a fundamental basic physiological drive which in turn is connected to many other aspects of physiology, in particular fertility and the immune response.

Professor Pete Artymiuk, from the University of Sheffield's Department of Molecular Biology and Biotechnology, said: "The human obesity receptor binds the hormone leptin and together they play a key role in regulating appetite, fertility, and immunity.

"Using X-ray crystallography we have solved the structure of the leptin-binding domain of the receptor bound to a potential therapeutic antibody that blocks leptin binding. This is the first crystal structure for any part of this important receptor.

"Because we now know the precise atomic structure of the receptor we can begin to design drug molecules that can alter its activity. This can be useful in the treatment of a variety of diseases ranging from obesity to autoimmune diseases including multiple sclerosis."


'/>"/>
Contact: Amy Pullan
a.l.pullan@sheffield.ac.uk
01-142-229-859
University of Sheffield
Source:Eurekalert

Related medicine news :

1. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
2. Founder and President of BOMF, Anne Mahlum, Speaks on How Running Helps to Tackle Homelessness, at National Press Club
3. Get up, get out and go: NC State research tackles childhood obesity
4. Kay's Naturals Answers Obama's Call to Tackle Childhood Obesity
5. Medical schools partner to tackle barriers to minority participation in cancer clinical trials
6. Iowan Tackles Everest and More in Unprecedented Adventure
7. Breast Cancer Survivor Tackles the Missing Link: Inspiring Event Offers Women Real Life Advice to Thrive After Medical Treatment Ends
8. Recent Book Moves Beyond Defensive Medicine, Tackles Entitlement Reform
9. Anemia tougher to tackle in black children with kidney disease
10. Global Alliance of Technological Universities (GlobalTech) to tackle Grand Challenges
11. Experts call for urgent action to tackle strong links between impotence and heart disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... 2017 , ... Studies show evidence that carotenoids and antioxidants derived either from ... these patients. , But how often do ophthalmologists and optometrists in Sweden recommend the ... of or with early symptoms of AMD? A study published recently in ...
(Date:6/23/2017)... ... 2017 , ... Everybody has their own personal preference when it comes to ... some people don't like it at all. FindaTopDoc took a look at what makes ... can give readers a taste of their deepest, darkest fantasies and has the ability ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State University will ... 20. , The two-day conference is focused on advancing scientific knowledge about the ... lives and eliminating racial breast cancer-related disparities. The conference theme is “Illuminating Actionable ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance ... With the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more ... 2012, the Biggert-Waters Act was enacted to reflect the actual risk in flood ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... planning services to communities in the greater Chicago metropolitan area, is embarking on ... to underprivileged youth in Chicago. , Founded in 1897, Hephzibah Children’s Association is ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 2017  Less than a month ago, amateur hackers ... companies, including hospital networks, in over 150 countries. ... the largest online extortion attempts ever recorded. With the ... is imperative that providers understand where the risks lie, ... — and many other very real cyber threats.  ...
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/3/2017)... INDIANAPOLIS , June 3, 2017  Eli ... today announced that results from the Phase 3 ... kinase (CDK)4 & 6 inhibitor, in combination with ... treatment with fulvestrant alone in women with hormone-receptor-positive ... advanced breast cancer who have relapsed or progressed ...
Breaking Medicine Technology: